Neoantigen Cancer Vaccine Market Size is Projected to Reach $1.38 billion by 2030: Straits Research
The growth of the market for Neoantigen cancer vaccines is primarily attributable to rapid technological advancements and improvements in the healthcare industry’s infrastructure. In addition to this, the increasing investments by governments and other healthcare providers are expected to create opportunities for the global neoantigen cancer vaccine market over the next few years.
New York, United States, Oct. 26, 2023 (GLOBE NEWSWIRE) — Neoantigens that arise from cancer-specific mutations are an additional class of antigens that are desirable for therapeutic cancer vaccines. Vaccination against tumour-specific neoantigens reduces the possibility of inducing central and peripheral tolerance, as well as the risk of autoimmunity. “Personalised medicines and Research and Development are driving the market,” states the Research Manager at Straits Research P. Ltd.
Download Free Sample Report PDF @ https://straitsresearch.com/report/neoantigen-cancer-vaccine-market/request-sample
Nowadays, due to sedentary lifestyles, unhealthy diets, and at times even some sorts of addiction are catering to a rise in numbers of cancer cases. This drives the market for cancer treatment and the Neoantigen Cancer Vaccines. With new research and development, now it can be assured that Cancer can be prevented as well as cured. As each person’s health conditions are different, each body’s response to medicine is different. So, with the increasing awareness, the adoption of Personalized Medicine to Tailor Patient Treatment on an Individual Level has increased. This boosts the market for Neoantigen Cancer Vaccines.
The growth of the market for Neoantigen cancer vaccines is primarily attributable to rapid technological advancements and improvements in the healthcare industry’s infrastructure. In addition to this, the increasing investments by governments and other healthcare providers are expected to create opportunities for the global neoantigen cancer vaccine market over the next few years. The new research and development are creating a lot of things for the market like reducing treatment gaps, reducing turnaround time and cost etc. This may boost the growth of the market in the near future. Also, the partnership and collaboration between various healthcare stakeholders are creating a room for further research and development, which is predicted to drive the market in future.
Due to the rising prevalence and incidence of lung cancer, melanoma, gastrointestinal, pancreatic cancer, and other solid tumor indications, North America is anticipated to be the leading regional market for neoantigen cancer vaccines over the forecast period. Countries like the United States of America are enriched with good healthcare infrastructure, and they are also investing massive amounts on research and development, making them the most dominant regions in the global Neoantigen Cancer Vaccine Market.
- The Global Neoantigen Cancer Vaccine Market is segmented on the basis of product, neoantigen type, administration route, cell, technology, delivery mechanism, application, region, and company.
- The North American region holds the largest market share in the Neoantigen Cancer Vaccine Market because of the development in technologies and healthcare infrastructure.
Key players working in the Global Neoantigen Cancer Vaccine Market include OSE Immunotherapeutics SA, Gritstone bio, Inc., BioNTech SE, F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., Moderna Inc., Avidea Technologies, Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene Co., Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath Biotherapeutics Co., Ltd., Vaximm AG, Medigene AG, Genocea Biosciences Inc., Advaxis, Inc., Nouscom AG etc. The companies operating in the market globally are aiming more towards expanding their share in the global market.
- In June, 2022, CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.
- In July 2021, BioNTech acquired Kite’s solid tumour neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility’s assets and leases in Gaithersburg, Maryland, US, strengthening its cell therapy pipeline.
- Personalised neo-antigen vaccine
- Off-the-shelf neoantigen vaccine
By Neoantigen Type:
- Synthetic Long Peptide
- Nucleic acid
- Dendritic cell
- Tumour cell
By Route of Administration:
- RNA Sequencing
- Whole Genome Sequencing
- HLA Typing
By Delivery Mechanism:
- Gene gun
- Brain cancer
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
Get Detailed Market Segmentation @ https://straitsresearch.com/report/neoantigen-cancer-vaccine-market/segmentation
About Straits Research Pvt Ltd.
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, specially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
For more information on your target market, please contact us below:
Phone: +1 646 480 7505 (the U.S.)
+91 8087085354 (APAC)
+44 208 068 9665 (the U.K.)
Email: [email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.